127 related articles for article (PubMed ID: 9573003)
1. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
3. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.
Rashidi A; Huselton EJ; Stefanski HE; DeFor TE; Shanley R; Choi J; DiPersio JF; Juckett M; Miller JS; Weisdorf DJ; Schroeder MA
Transplant Cell Ther; 2023 May; 29(5):328.e1-328.e6. PubMed ID: 36804933
[TBL] [Abstract][Full Text] [Related]
5. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.
Minculescu L; Reekie J; Petersen SL; Kornblit BT; Schjoedt I; Andersen NS; Andersen LP; Fischer-Nielsen A; Haastrup EK; Friis LS; Sengelov H
Acta Haematol; 2024; 147(3):325-332. PubMed ID: 37827141
[TBL] [Abstract][Full Text] [Related]
6. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
Marijt WA; Heemskerk MH; Kloosterboer FM; Goulmy E; Kester MG; van der Hoorn MA; van Luxemburg-Heys SA; Hoogeboom M; Mutis T; Drijfhout JW; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2742-7. PubMed ID: 12601144
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.
Ash S; Stein J; Askenasy N; Yaniv I
Br J Cancer; 2010 Nov; 103(10):1597-605. PubMed ID: 20978501
[TBL] [Abstract][Full Text] [Related]
8. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects.
Miyake T; Hosaka N; Cui W; Nishida T; Takaki T; Inaba M; Kamiyama Y; Ikehara S
Immunology; 2009 Apr; 126(4):552-64. PubMed ID: 18778285
[TBL] [Abstract][Full Text] [Related]
9. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K; Antin JH
Front Immunol; 2024; 15():1328858. PubMed ID: 38558819
[TBL] [Abstract][Full Text] [Related]
10. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract][Full Text] [Related]
11. Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.
Willems L; Fevery S; Sprangers B; Rutgeerts O; Lenaerts C; Ibrahimi A; Gijsbers R; Van Gool S; Waer M; Billiau AD
Cancer Immunol Immunother; 2013 Nov; 62(11):1733-44. PubMed ID: 24081484
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.
Maung KK; Chen BJ; Barak I; Li Z; Rizzieri DA; Gasparetto C; Sullivan KM; Long GD; Engemann AM; Waters-Pick B; Nichols KR; Lopez R; Kang Y; Sarantopoulos S; Sung AD; Chao NJ; Horwitz ME
Bone Marrow Transplant; 2021 Jan; 56(1):137-143. PubMed ID: 32624583
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Zhang W; Choi J; Zeng W; Rogers SA; Alyea EP; Rheinwald JG; Canning CM; Brusic V; Sasada T; Reinherz EL; Ritz J; Soiffer RJ; Wu CJ
Clin Cancer Res; 2010 May; 16(10):2729-39. PubMed ID: 20460482
[TBL] [Abstract][Full Text] [Related]
14. Severe Liver Dysfunction after Donor Lymphocyte Infusion for Relapsed Multiple Myeloma.
No TH; Heo NY; Park SH; Choi JH; Lee J; Lim SN; Park SY
Korean J Gastroenterol; 2024 Mar; 83(3):123-126. PubMed ID: 38522856
[TBL] [Abstract][Full Text] [Related]
15. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
16. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
17. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis.
Troullioud Lucas AG; Lindemans CA; Bhoopalan SV; Dandis R; Prockop SE; Naik S; Keerthi D; de Koning C; Sharma A; Nierkens S; Boelens JJ
Cytotherapy; 2023 Sep; 25(9):977-985. PubMed ID: 37330731
[TBL] [Abstract][Full Text] [Related]
18. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter DL; Alyea EP; Antin JH; DeLima M; Estey E; Falkenburg JH; Hardy N; Kroeger N; Leis J; Levine J; Maloney DG; Peggs K; Rowe JM; Wayne AS; Giralt S; Bishop MR; van Besien K
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1467-503. PubMed ID: 20699125
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.
Marcondes AM; Li X; Tabellini L; Bartenstein M; Kabacka J; Sale GE; Hansen JA; Dinarello CA; Deeg HJ
Blood; 2011 Nov; 118(18):5031-9. PubMed ID: 21900190
[TBL] [Abstract][Full Text] [Related]
20. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34
Indran T; Das T; Muirhead J; O'Brien M; Swain MI; Cirone B; Widjaja J; Patil S; Curtis DJ
Leuk Res; 2024 Apr; 142():107504. PubMed ID: 38703634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]